Ryan J Sullivan Selected Research

pembrolizumab

2/2024	Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
1/2024	Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
12/2023	Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
12/2023	Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
8/2023	Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy.
1/2023	The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
1/2023	Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
6/2022	STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.
12/2021	For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti-PD-1-Resistant Melanoma.
1/2021	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryan J Sullivan Research Topics

Disease

136	Melanoma (Melanoma, Malignant) 06/2024 - 05/2009
108	Neoplasms (Cancer) 05/2024 - 05/2009
16	Brain Neoplasms (Brain Tumor) 12/2023 - 05/2015
15	Neoplasm Metastasis (Metastasis) 01/2024 - 10/2013
14	Disease Progression 01/2024 - 11/2012
10	Uveal melanoma 04/2024 - 10/2013
9	Myocarditis (Carditis) 12/2022 - 01/2018
7	Colitis 05/2024 - 01/2016
6	Cardiogenic Shock 01/2021 - 01/2016
5	Fever (Fevers) 12/2023 - 07/2008
5	Heart Block 01/2021 - 01/2018
4	Pruritus (Itching) 04/2024 - 01/2021
4	COVID-19 04/2024 - 01/2020
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 09/2016
4	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 12/2019
4	Inflammation (Inflammations) 01/2021 - 11/2019
4	Heart Arrest (Cardiac Arrest) 01/2021 - 01/2018
4	Kaposi Sarcoma (Kaposi's Sarcoma) 12/2010 - 06/2008
3	Sarcoma (Soft Tissue Sarcoma) 06/2024 - 11/2020
3	Lung Neoplasms (Lung Cancer) 05/2024 - 01/2020
3	Exanthema (Rash) 04/2024 - 01/2021
3	Circulating Neoplastic Cells 03/2024 - 11/2014
3	Carcinogenesis 03/2023 - 04/2007
3	Hypophysitis 01/2023 - 01/2018
3	Meningeal Carcinomatosis 10/2021 - 01/2020
3	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 01/2018
2	Hepatitis 12/2023 - 01/2021
2	Pneumonia (Pneumonitis) 06/2023 - 11/2019
2	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 04/2022
2	Autoimmune Diseases (Autoimmune Disease) 12/2022 - 02/2016
2	Anaplastic Thyroid Carcinoma 04/2022 - 01/2018
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2022 - 10/2020
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2021 - 07/2021
2	Histiocytic Sarcoma 10/2021 - 01/2020
2	Wounds and Injuries (Trauma) 07/2021 - 07/2008
2	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2019
2	Infections 12/2010 - 01/2009
1	Hypoxia (Hypoxemia) 05/2024
1	Hyponatremia 04/2024
1	Anemia 04/2024

Drug/Important Bio-Agent (IBA)

79	Immune Checkpoint InhibitorsIBA 05/2024 - 03/2013
23	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2024 - 03/2013
20	IpilimumabIBA 12/2023 - 11/2012
18	trametinibIBA 05/2024 - 03/2013
18	pembrolizumabIBA 02/2024 - 10/2013
16	dabrafenibIBA 05/2024 - 03/2013
15	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2014
14	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2012
10	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 06/2024 - 07/2008
10	NivolumabIBA 04/2024 - 10/2013
10	Proteins (Proteins, Gene)FDA Link 03/2024 - 10/2013
10	Interleukin-2 (IL2)IBA 01/2023 - 01/2012
10	AntibodiesIBA 01/2022 - 10/2013
9	AntigensIBA 02/2024 - 03/2013
9	LigandsIBA 01/2023 - 03/2013
7	Phosphotransferases (Kinase)IBA 04/2022 - 01/2014
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023 - 10/2013
6	SteroidsIBA 01/2023 - 01/2018
6	VemurafenibIBA 01/2019 - 03/2013
5	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 10/2021
5	CytokinesIBA 04/2022 - 04/2010
5	Monoclonal AntibodiesIBA 11/2021 - 06/2008
5	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2018
4	GlucocorticoidsIBA 12/2023 - 01/2018
4	CTLA-4 AntigenIBA 01/2023 - 01/2017
3	ulixertinibIBA 04/2024 - 01/2018
3	Anti-Bacterial Agents (Antibiotics)IBA 04/2024 - 07/2008
3	Mitogen-Activated Protein KinasesIBA 03/2024 - 01/2014
3	Cell-Free Nucleic AcidsIBA 01/2024 - 11/2014
3	tebentafuspIBA 12/2023 - 01/2021
3	HLA-A Antigens (HLA-A)IBA 12/2023 - 01/2021
3	Programmed Cell Death 1 ReceptorIBA 10/2023 - 01/2019
3	B7-H1 AntigenIBA 10/2023 - 03/2015
3	binimetinibIBA 06/2022 - 05/2020
3	encorafenibIBA 06/2022 - 05/2020
3	VaccinesIBA 04/2022 - 01/2018
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2020
2	EnzymesIBA 02/2024 - 01/2022
2	Messenger RNA (mRNA)IBA 01/2024 - 01/2014
2	Dacarbazine (DIC)FDA LinkGeneric 12/2023 - 01/2021
2	Glycoproteins (Glycoprotein)IBA 12/2023 - 01/2021
2	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2021
2	Imatinib Mesylate (Gleevec)FDA Link 11/2022 - 05/2015
2	CohesinsIBA 01/2022 - 01/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 12/2020
2	AntioxidantsIBA 01/2021 - 09/2009
2	Small Interfering RNA (siRNA)IBA 11/2020 - 12/2015
2	Oxidoreductases (Dehydrogenase)IBA 01/2018 - 10/2007
2	Tyrosine Kinase InhibitorsIBA 09/2016 - 05/2015
1	Amylases FDA Link 04/2024
1	Vancomycin FDA LinkGeneric 04/2024
1	navitoclaxIBA 03/2024

Therapy/Procedure

118	Therapeutics 06/2024 - 01/2009
45	Immunotherapy 02/2024 - 03/2013
6	Aftercare (After-Treatment) 12/2023 - 01/2016
6	Drug Therapy (Chemotherapy) 10/2023 - 08/2015
5	Radiotherapy 07/2021 - 08/2015
3	Molecular Targeted Therapy 10/2013 - 05/2009
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023 - 04/2022
1	Adjuvant Radiotherapy 06/2024